Ellen Gail Duysen

Ellen Gail Duysen

Auto-generated profile, based on publicly available information

Ellen Gail Duysen

University of Nebraska Medical Center

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2002 in Neuroscience
Verified
Journal Article
Closed access
MMM.-M Mesulam
M.-M Mesulam
AGA Guillozet
A Guillozet
PSP Shaw
P Shaw
ALA Levey
A Levey
EDE.G Duysen
E.G Duysen
OLO Lockridge
O Lockridge

1 November 2005 in Biochemical Pharmacology
Verified
Journal Article
Closed access
BLBin Li
Bin Li
MSMeghan Sedlacek
Meghan Sedlacek
IMIndumathi Manoharan
Indumathi Manoharan
RBRathnam Boopathy
Rathnam Boopathy
EDEllen G. Duysen
Ellen G. Duysen
OLOksana Lockridge
Oksana Lockridge

17 November 2006 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
JHJoachim Hartmann
Joachim Hartmann
CKCornelia Kiewert
Cornelia Kiewert
EDEllen G. Duysen
Ellen G. Duysen
OLOksana Lockridge
Oksana Lockridge
NGNigel H. Greig
Nigel H. Greig
JKJochen Klein
Jochen Klein
Central cholinergic systems are involved in a plethora of brain functions and are severely and selectively damaged in neurodegenerative diseases such as Alzheimer’s disease and dementia with Lewy bodies. Cholinergic dysfunction is treated with inhibitors of acetylcholinesterase (AChE) while the role of butyrylcholinesterase (BChE) for brain cholinergic function is unclear. We have usedin vivomicrodialysis to investigate the regulation of hippocampal acetylcholine (ACh) levels in mice that are devoid of AChE (AChE‐/‐ mice). Extracellular ACh levels in the hippocampus were 60‐fold elevated in AChE‐/‐ mice compared with wild‐type (AChE+/+) animals. In AChE‐/‐ mice, calcium‐free conditions reduced hippocampal ACh levels by 50%, and infusion of tetrodotoxin by more than 90%, indicating continuous ACh release. Infusion of a selective AChE inhibitor (BW284c51) caused a dose‐dependent, up to 16‐fold increase of extracellular ACh levels in AChE+/+ mice but did not change ACh levels in AChE‐/‐ mice. In contrast, infusion of a selective inhibitor of BChE (bambuterol) caused up to fivefold elevation of ACh levels in AChE‐/‐ mice, but was without effect in AChE+/+ animals. These results were corroborated with two other specific inhibitors of AChE and BChE, tolserine and bis‐norcymserine, respectively. We conclude that lack of AChE causes dramatically increased levels of extracellular ACh in the brain. Importantly, in the absence of AChE, the levels of extracellular ACh in the brain are controlled by the activity of BChE. These results point to a potential usefulness of BChE inhibitors in the treatment of central cholinergic dysfunction in which brain AChE activity is typically reduced.

3 November 2004 in Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
EPEric S Peeples
Eric S Peeples
LSLawrence M. Schopfer
Lawrence M. Schopfer
EDEllen G. Duysen
Ellen G. Duysen
RSReggie Spaulding
Reggie Spaulding
TVTroy Voelker
Troy Voelker
OLOksana Lockridge
Oksana Lockridge
The classical laboratory tests for exposure to organophosphorus toxicants (OP) are inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activity in blood. In a search for new biomarkers of OP exposure, we treated mice with a biotinylated organophosphorus agent, FP-biotin. The biotinylated proteins in muscle were purified by binding to avidin-Sepharose, separated by gel electrophoresis, digested with trypsin, and identified from their fragmentation patterns on a quadrupole time-of-flight mass spectrometer. Albumin and ES1 carboxylesterase (EC 3.1.1.1) were found to be major targets of FP-biotin. These FP-biotinylated proteins were also identified in mouse plasma by comparing band patterns on nondenaturing gels stained for albumin and carboxylesterase activity, with band patterns on blots hybridized with Streptavidin Alexa-680. Two additional FP-biotin targets, AChE (EC 3.1.1.7) and BChE (EC 3.1.1.8), were identified in mouse plasma by finding that enzyme activity was inhibited 50–80%. Mouse plasma contained eight additional FP-biotinylated bands whose identity has not yet been determined. In vitro experiments with human plasma showed that chlorpyrifos oxon, echothiophate, malaoxon, paraoxon, methyl paraoxon, diazoxon, diisopropylfluorophosphate, and dichlorvos competed with FP-biotin for binding to human albumin. Though experiments with purified albumin have previously shown that albumin covalently binds OP, this is the first report of OP binding to albumin in a living animal. Carboxylesterase is not a biomarker in man because humans have no carboxylesterase in blood. It is concluded that OP bound to albumin could serve as a new biomarker of OP exposure in man.

1 July 2002 in Developmental Brain Research
Verified
Journal Article
Closed access
EDEllen G Duysen
Ellen G Duysen
JSJudith A Stribley
Judith A Stribley
DFDebra L Fry
Debra L Fry
SHSteven H Hinrichs
Steven H Hinrichs
OLOksana Lockridge
Oksana Lockridge

1 November 2001 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
EDEllen G. Duysen
Ellen G. Duysen
BLBin Li
Bin Li
WXWeihua Xie
Weihua Xie
LSLawrence M. Schopfer
Lawrence M. Schopfer
RARobert S. Anderson
Robert S. Anderson
OLOksana Lockridge
Oksana Lockridge